Evidence map›Paper›PMID 31933800›Full record

ArticleInternational journal of clinical and experimental pathology2019

Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways.

Min-Hua Rong, Kai-Teng Cai, Hui-Ping Lu, Yi-Nan Guo, Xiong-Yan Huang, Zhan-Hui Zhu, Wei Tang, Su-Ning Huang

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. MicroRNA-452: a double-edged sword in multiple human cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Min-Hua RongResearch Department, Affiliated Cancer Hospital, Guangxi Medical University 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Kai-Teng CaiResearch Department, Affiliated Cancer Hospital, Guangxi Medical University 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Hui-Ping LuDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Yi-Nan GuoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Xiong-Yan HuangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Zhan-Hui ZhuResearch Department, Affiliated Cancer Hospital, Guangxi Medical University 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Wei TangDepartment of Breast Surgery, Affiliated Cancer Hospital, Guangxi Medical University 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Su-Ning HuangDepartment of Radiotherapy, Affiliated Cancer Hospital, Guangxi Medical University 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe implication of miR-452-5p and its prospective machinery in hepatocellular carcinoma (HCC) remains largely unknown. For this reason, this study aimed to inspect the clinical implication of miR-452-5p expression in HCC tissues with multiple detection approaches, to analyze its potential function via

methodsThe assessment of the expression level of miR-452-5p in HCC was conducted via four methods: 1) in-house real-time quantitative PCR (RT-qPCR), 2) miRNA-sequencing (miRNA-seq) from The Cancer Genome Atlas (TCGA), 3) miRNA microarrays from the Gene Expression Omnibus (GEO), and 4) comprehensive meta-analyses calculating the standard mean difference (SMD) and summary of receiver operator characteristic (sROC). Following the target prediction, one of the potential targets of miR-452-5p was validated through a dual-luciferase reporter assay.

resultsMiR-452-5p was consistently elevated in HCC tissues via various detection methods, including in-house RT-qPCR, miRNA-seq, and miRNA microarrays. The final SMD was 0.842 for 820 cases of HCC samples. Simultaneously, the area under curve (AUC) of the sROC was 0.80 (0.76-0.83). The 1,135 predicted targets of miR-452-5p were enriched in the pathways of cytokine-cytokine receptor interaction, carbon metabolism, and complement and coagulation cascades. Among these predicted targets, CDKN1B was verified to be a real target of miR-452-5p.

conclusionThe overexpression of miR-452-5p may play a pivotal role in the carcinogenesis of HCC via targeting multiple signaling pathways and genes. The function and molecular machinery of miR-452-5p in HCC requires further in-depth exploration.

Indexed as

CDKN1BHepatocellular carcinoma (HCC)MiR-452-5psignaling pathways

Identifiers

PMID31933800
PMCPMC6949781
OpenAlexW3009963254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.